ABVC BioPharma Reports Over $1 Million in Q3 Licensing Revenues, Strengthening High-Margin Business

ABVC BioPharma, Inc. (NASDAQ: ABVC) announced it has received a licensing payment of $145,950 from OncoX BioPharma, Inc., bringing total payments from OncoX in the third quarter of 2025 to $595,950. This contributes to the company's consolidated licensing revenues of $1,275,950 for Q3 to date across multiple partnerships, including AiBtl BioPharma and ForSeeCon Eye Corporation. These revenues significantly strengthen ABVC's cash position and profitability due to their high-margin nature, as development expenses were largely incurred in prior years, minimizing incremental operating costs.

Dr. Uttam Patil, ABVC's Chief Executive Officer, emphasized that these milestone revenues underscore the reliability of the company's licensing framework and directly enhance its high-margin profile and long-term growth strategy. OncoX, a clinical-stage biopharmaceutical company focused on next-generation cancer immunotherapies derived from natural sources, has licensed four IND-approved oncology assets from ABVC and is expanding its portfolio, including the anticipated acquisition of the Lycogen® lycopene platform. This platform targets adjacent fields such as preventative medicine, chronic disease care, aesthetic medicine, and animal health, with a projected global market size of $187 million by 2030, according to Allied Market Research.

OncoX operates under a strategic collaboration with BioKey Inc., a U.S. FDA-registered facility, and aims to expand its global footprint in markets including the United States, Japan, and Taiwan. The total potential deal proceeds from the OncoX agreement could reach $105 million if all milestone payments are achieved, though there is no guarantee of such outcomes. ABVC BioPharma itself is a clinical-stage company with a pipeline of six drugs and one medical device under development, leveraging technology from institutions like Stanford University and University of California at San Francisco. Investors are advised to review detailed risk factors in the company's filings with the Securities and Exchange Commission, available at http://www.sec.gov, as forward-looking statements involve uncertainties and risks that could affect actual results.